Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously
Get the next $LUNG alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $LUNG
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2025 | $17.00 | Buy | D. Boral Capital |
| 12/11/2024 | $17.00 → $7.50 | Buy → Neutral | Citigroup |
| 6/4/2024 | $12.00 | Buy | Lake Street |
| 2/23/2024 | $16.00 → $14.00 | Overweight → Equal Weight | Wells Fargo |
| 9/5/2023 | $18.00 | Buy | Craig Hallum |
| 2/27/2023 | $10.00 → $15.00 | Equal Weight → Overweight | Wells Fargo |
| 1/3/2023 | $8.00 | Neutral → Underperform | BofA Securities |
| 12/12/2022 | $14.00 → $10.00 | Neutral → Buy | Citigroup |
Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni
EDAP Appoints Glen French to Board of Directors
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. "We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world's premier robotic HIFU technology platform."
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20
D. Boral Capital initiated coverage on Pulmonx with a new price target
D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00
Pulmonx downgraded by Citigroup with a new price target
Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously
Lake Street initiated coverage on Pulmonx with a new price target
Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00
Director French Glendon E. Iii sold $157,000 worth of shares (20,000 units at $7.85), decreasing direct ownership by 2% to 991,974 units (SEC Form 4)
4 - Pulmonx Corp (0001127537) (Issuer)
Chief Financial Officer & PAO Joshi Mehul sold $102,414 worth of shares (14,384 units at $7.12) and was granted 108,000 shares, increasing direct ownership by 73% to 221,986 units (SEC Form 4)
4 - Pulmonx Corp (0001127537) (Issuer)
PRESIDENT AND CEO Williamson Steven S. sold $197,699 worth of shares (27,689 units at $7.14) and was granted 181,696 shares, increasing direct ownership by 69% to 376,038 units (SEC Form 4)
4 - Pulmonx Corp (0001127537) (Issuer)
SEC Form DEFA14A filed by Pulmonx Corporation
DEFA14A - Pulmonx Corp (0001127537) (Filer)
SEC Form DEF 14A filed by Pulmonx Corporation
DEF 14A - Pulmonx Corp (0001127537) (Filer)
SEC Form S-8 filed by Pulmonx Corporation
S-8 - Pulmonx Corp (0001127537) (Filer)
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors
LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir
Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20
Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive trea
Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation
SC 13G/A - Pulmonx Corp (0001127537) (Subject)